Clinical Trial Update: Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating fulvestrant with or without bortezomib in patients with operable locally advanced or metastatic estrogen receptor–positive breast can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2023-11-27